

## Vitrakvi - (25 mg and 100 mg ; Capsule)

<b>Generic Name</b>	Larotrectinib Sulfate	<b>Innovator</b>	Bayer
<b>Dosage</b>	25 mg and 100 mg ; Capsule	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	Less Than 5
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: ? have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have no satisfactory alternative treatments or that have progressed following treatment.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Vitrakvi - (EQ 20MG BASE/ML ; Solution)

<b>Generic Name</b>	Larotrectinib Sulfate	<b>Innovator</b>	Bayer
<b>Dosage</b>	EQ 20MG BASE/ML ; Solution	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: ? have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, ? are metastatic or where surgical resection is likely to result in severe morbidity, and ? have no satisfactory alternative treatments or that have progressed following treatment.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.